1. Clinical Overview

Molecule: Synthetic heptapeptide from tuftsin (Thr-Lys-Pro-Arg) + stabilizing Pro-Gly-Pro

Classification: Anxiolytic neuropeptide • Nootropic • Neuroimmune modulator • Anti-fatigue/anti-stress • Mood-stabilizing • Non-sedating (GABA-modulating) • Anti-inflammatory CNS

Key Advantage: Benzodiazepine-like anxiolysis WITHOUT sedation, addiction, withdrawal, memory impairment, or motor impairment. Widely used in Eastern European neuropsychiatric settings.

2. Mechanisms of Action

2.1 GABAergic Modulation (Primary)

Increases GABA receptor affinity: calmness, relaxation, anxiety reduction, emotional stability. No receptor downregulation, no dependence, no tolerance.

2.2 BDNF Upregulation

Increases BDNF in hippocampus and prefrontal cortex: improved learning, memory consolidation, synaptic plasticity, stress resilience.

2.3 Dopamine & Serotonin

Stabilizes monoamine balance: ↑ serotonin, ↑ dopamine in PFC, ↓ excessive norepinephrine-driven anxiety. Both anxiolytic and cognitive-enhancing.

2.4 Tuftsin Immunomodulation

Modulates cytokine balance, T-cell activity, anti-inflammatory CNS responses, stress-induced immune suppression. Neuroimmune resilience for chronic stress.

2.5 Anti-Fatigue

Reduces mental fatigue, cognitive burnout, stress-induced energy collapse. Executives, cognitive workers, students.

3. Clinical Applications

3.1 Anxiety & Mood

GAD, stress-induced, social, high-performance anxiety, irritability/volatility.

3.2 Cognitive Enhancement

Working memory, verbal recall, learning speed, attention, executive function. Synergistic with Pinealon and Semax.

3.3 ADHD Adjunct

Calm focus, reduced over-arousal, improved executive functioning. Adjunctive, not standalone.

3.4 Neuroimmune

Neuroinflammation, immune stress, cytokine dysregulation. Post-viral decline, chronic stress, autoimmune CNS.

3.5 Withdrawal Support

Alcohol withdrawal anxiety, benzodiazepine taper, nicotine craving. Adjunctive.

3.6 Burnout & Fatigue

Chronic stress, overwork, mental burnout. Combined with DSIP for restorative sleep synergy.

4. Administration & Protocols

4.1 Intranasal (Preferred)

Standard: 250–500 mcg IN 1–2×/day
High-Stress: 750–1,000 mcg IN 1–2×/day
Acute: 250–500 mcg PRN | Onset 5–15 min | Duration 4–6 hrs

4.2 Subcutaneous

250–500 mcg SC daily. Slower onset, more stable systemic effect.

4.3 Sublingual

600–1,200 mcg SL 1–2×/day if IN not tolerated.

Cycling

Daily × 10–30 days, or 3–5×/week maintenance, or PRN. No receptor desensitization.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ Semax: Top cognitive duo — calm focus (Selank) + neurostimulatory nootropic (Semax)
+ Pinealon: Mitochondrial/neural repair + mood/focus stability — aging
+ DSIP: Deep restoration — sleep architecture + daytime calm
+ Oxytocin Acetate: Emotional bonding, relationship anxiety, intimacy
+ MOTS-c / SS-31: Neuroenergy deficits + mood dysregulation
+ Tesofensine: Balances stimulant effects with anxiolytic calm

6. Clinical Decision Trees

Tree 1 — Is Selank Indicated?

Anxiety present? → YES

Focus impaired by stress? → YES

Poor emotional regulation? → YES

Stimulant jitteriness? → YES

Chronic stress / burnout? → YES

Severe depression? → Adjunctive only

Tree 2 — Dosing

General anxiety → 250–500 mcg IN 1–2×/day

High anxiety / acute → 500–1,000 mcg IN PRN

Cognitive enhancement → 250–500 mcg IN AM

ADHD adjunct → 250–500 mcg IN 2–3×/day

Maintenance → 250 mcg IN 3–5×/week

7. Integrated Archetypes

A — Calm Focus / Productivity

Selank IN daily + Semax AM + Pinealon mitochondrial support
Outcome: Productive calm + cognitive stamina.

B — Anxiety / Stress Recovery

Selank 500 mcg IN PRN/daily + DSIP nightly + Oxytocin + Mg glycinate
Outcome: Stabilized mood, reduced reactivity.

C — Executive Burnout

Selank AM + MOTS-c weekly + SS-31 neuroenergy + NAD+ cellular recovery
Outcome: Reversal of mental fatigue and burnout.

D — Post-Viral Brain Fog

Selank daily + Pinealon + KPV inflammation + Omega-3 DHA
Outcome: Reduced cognitive fog, improved clarity.

8. Expected Timeline

5–15 min: Onset of calmness & focus
Day 1–3: Noticeable anxiety reduction
Week 1–2: Improved cognition, mood stability
Week 2–4: Significant emotional resilience
Long-term: Consistent mood & cognitive enhancement

9. Contraindications

Absolute

Relative

10. Adverse Effects

Extremely well tolerated. Possible: mild nasal irritation, lightheadedness, transient fatigue, mild headache, emotional flattening at very high doses (rare). No sedation, dependence, or withdrawal.

11. Monitoring

Legal Disclaimer

This document is provided solely for educational and informational purposes. Selank and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Selank

Foundational Discovery
1. Ashmarin, I. P., et al. Synthetic regulatory peptides including Selank. Russ J Physiol, 86(3), 401–410 (2000).
2. Kozlovskaya, M. M., et al. Pharmacological profile. Bull Exp Biol Med, 139(3), 363–365 (2005).
3. Ashmarin, I. P., et al. Heptapeptide neuromodulatory effects. Biochemistry (Moscow), 70(2), 231–236 (2005).
4. Kamensky, A. A., et al. Structure-function of TP-7. Neurochem J, 1(1), 33–39 (2007).
Anxiolytic & Stress
5. Andreeva, L. A., et al. Anxiolytic effects comparable to benzodiazepines. J Pharmacol Exp Ther, 315(1), 308–314 (2005).
6. Galina, T. V., et al. Anxiolytic activity in stress models. Neurosci Behav Physiol, 38(6), 639–643 (2008).
7. Seredenin, S. B., et al. Reduces anxiety in chronic stress. Neurochem J, 2(1), 53–60 (2008).
8. Kubatiev, A. A., et al. Corticosterone/HPA modulation. Bull Exp Biol Med, 147(2), 180–183 (2009).
Cognition & Memory
9. Andreeva, L. A., et al. Learning and memory consolidation. Neurosci Lett, 398(3), 322–327 (2006).
10. Khaustova, S. A., et al. BDNF and synaptic plasticity. J Mol Neurosci, 51(1), 110–118 (2013).
11. Kozlovskaya, M. M., et al. Monoamine metabolism and cognition. Neurochem J, 3(4), 255–261 (2009).
12. Inozemtseva, L. S., et al. Attention and working memory in neurasthenia. Russ Clin Psychiatry, 2, 64–71 (2012).
Immunomodulation
13. Gusev, K. A., et al. Cytokine production and immune balance. Bull Exp Biol Med, 151(5), 612–615 (2011).
14. Andreeva, L. A., et al. Macrophage activation and antiviral response. Immunol Lett, 116(1), 65–71 (2008).
15. Ho, L. T., et al. Th1/Th2 immune polarization. Int Immunopharmacol, 9(7–8), 828–835 (2009).
Neurotransmitter Regulation
16. Kozlovskaya, M. M., et al. Serotonin and dopamine metabolism. J Neurochem, 108(3), 645–656 (2009).
17. Dubrovina, N. I., et al. GABAergic anxiolytic mechanism. Behav Pharmacol, 18(8), 695–702 (2007).
18. Andreeva, L. A., et al. Noradrenergic signaling regulation. Neurosci J, 16(2), 113–120 (2010).
Neuroprotection
19. Shataeva, L. K., & Miasoedov, N. F. Protects neurons in oxidative/ischemic stress. Neurosci Behav Physiol, 39(3), 283–289 (2009).
20. Vetvicka, V., & Vetvickova, J. Peptide bioregulators and neuroimmune resilience. Biomed Pharmacother, 65(2), 67–72 (2011).
21. Dubynin, V. A., et al. Anti-apoptotic via mitochondrial stabilization. Exp Biol Med, 236(7), 862–868 (2011).
Human Clinical Trials
22. Seredenin, S. B., et al. Anxiety and asthenic disorders. Eksp Klin Farmakol, 70(3), 54–58 (2007).
23. Khaustova, S. A., et al. Cognitive/emotional status in chronic fatigue. Human Physiol, 36(1), 101–107 (2010).
24. Neznamov, G. G., & Nagornev, V. A. GAD controlled clinical trial. Clin Psychiatry, 1, 36–43 (2009).
Safety & Toxicology
25. Seredenin, S. B., et al. Non-toxic, no dependence. Bull Exp Biol Med, 132(2), 109–112 (2001).
26. Ashmarin, I. P., et al. Safety of short regulatory peptides. Cell Tissue Biol, 5(4), 299–307 (2011).
27. Golubeva, T. N., et al. Chronic safety profile. Exp Biol Med, 239(3), 304–311 (2014).